Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

70results about How to "Minimise concentration" patented technology

Cannula stent

A stent (30) formed from cannula and having flexible segments (31) and high hoop strength segments (32) alternating therealong. Longitudinal struts or tie bars (41) interconnect the segments. Minimal length reduction of the strut occurs upon expansion. In the high hoop strength segment (32), struts (37) in a zig-zag configuration (Gianturco Z-stent) are initially parallel in the unexpanded strut condition. In the flexible segment (31), struts (58) extend from a respective C-shaped bend (59) to converge at the opposite ends thereof when unexpanded. In one embodiment, certain adjacent struts (39–41) of the hoop segment are spaced apart by elongated openings or gaps (46, 48) interposed therebetween and interconnected at their respective ends (42, 44) to form a T-shaped strut interconnection (45). The selected width (50, 51) of the first and third struts (54, 57) increases toward the ends (47, 48) of the elongated openings (46, 48) adjacent the strut interconnection (45). This strut width increase about one end of the strut significantly reduces the tensile strain exhibited about the opening end when the stent is radially expanded during manufacture. The tip length (52, 55) of the struts about the interconnection (45) is also adjusted (increased) along with the other C-shaped strut interconnections (59, 71) to further distribute the tensile strain developed during radial expansion.
Owner:COOK MEDICAL TECH LLC

Method of fabricating thin film transistor

Disclosed is a method of fabricating a thin film transistor in which, in order to control the concentration of metal catalysts remaining on a polycrystalline silicon layer when an amorphous silicon layer formed on an insulating substrate is crystallized into the polycrystalline silicon layer by a super grain silicon (SGS) crystallization method, the substrate is annealed so that a very small amount of metal catalyst is adsorbed or diffused into a capping layer, and then a crystallization process is carried out, thereby minimizing the concentration of the metal catalysts remaining on the polycrystalline silicon layer, as well as forming a thick metal catalyst layer. The method includes preparing an insulating substrate; sequentially forming an amorphous silicon layer, a capping layer, and a metal catalyst layer on the substrate; first annealing the substrate to adsorb or diffuse metal catalysts into the capping layer; removing the metal catalyst layer; second annealing the substrate to crystallize the amorphous silicon layer into a polycrystalline silicon layer by means of the metal catalyst; and removing the capping layer. Thus, with the method of fabricating the thin film transistor of the present invention, it is possible to minimize the concentration of the metal catalysts remaining on the polycrystalline silicon layer, as well as to form a thick metal catalyst layer.
Owner:SAMSUNG DISPLAY CO LTD

Angiogenically effective unit dose of FGF-2 and method of use

The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 μg/kg to 48 μg/kg of an FGF-2 of SEQ ID NO: 2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. In another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. The single unit dose composition of the present invention provides an angiogenic effect in a human CAD patient that lasts 2 months before re-treatment is required. In another aspect, the present invention is directed to a method of administration which optimizes patient's safety. In this embodiment, fluids, heparin and/or rate of infusion all play a role. In another aspect, the present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier. The magnitude and duration of benefit were unexpected; in addition benefit with the IV route was unexpected.
Owner:NOVARTIS VACCINES & DIAGNOSTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products